References
- Martin-Gandul C, Mueller NJ, Pascual M, et al. The impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation. Am J Transplant. 2015 Dec;15(12):3024–3040. DOI:https://doi.org/10.1111/ajt.13486.
- van Delden C, Stampf S, Hirsch HH, et al. Burden and timeline of infectious diseases in the first year after solid organ transplantation in the swiss transplant cohort study. Clin Infect Dis. 2020 Oct 23;71(7):e159–e169.
- Danziger-Isakov L, Blumberg EA, Manuel O, et al. Impact of COVID-19 in solid organ transplant recipients. Am J Transplant. 2021 Mar;21(3):925–937. DOI:https://doi.org/10.1111/ajt.16449.
- World Health Organization (WHO). Coronavirus (COVID-19) Dashboard. [Accessed on 1 September 2021]. https://covid19.who.int/
- Azzi Y, Bartash R, Scalea J, et al. COVID-19 and solid organ transplantation: a review article. Transplantation. 2021 Jan 1;105(1):37–55.
- Linares L, Cofan F, Diekmann F, et al. A propensity score-matched analysis of mortality in solid organ transplant patients with COVID-19 compared to non-solid organ transplant patients. PLoS One. 2021;16(3):e0247251. DOI:https://doi.org/10.1371/journal.pone.0247251.
- Rinaldi M, Bartoletti M, Bussini L, et al. COVID-19 in solid organ transplant recipients: no difference in survival compared to general population. Transpl Infect Dis. 2021 Feb;23(1):e13421. DOI:https://doi.org/10.1111/tid.13421.
- Kates OS, Haydel BM, Florman SS, et al. COVID-19 in solid organ transplant: a multi-center cohort study. Clin Infect Dis. 2020 Aug 7. DOI:https://doi.org/10.1093/cid/ciaa1097.
- Lubetzky M, Aull MJ, Craig-Schapiro R, et al. Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a New York City transplant center. Nephrol Dial Transplant. 2020 Jul 1;35(7):1250–1261.
- Ball P. The lightning-fast quest for COVID vaccines - and what it means for other diseases. Nature. 2021 Jan;589(7840):16–18.
- Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403–416.
- Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603–2615.
- Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021 Aug 12;385(7):585–594.
- Ravanan R, Mumford L, Ushiro-Lumb I, et al. Two Doses of SARS-CoV-2 Vaccines reduce risk of Death Due to COVID-19 in solid organ transplant recipients: preliminary outcomes from a UK registry linkage analysis. Transplantation. 2021 Nov 1;105(11):e263–e264.
- Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-Dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021 Jun 1;325(21):2204–2206. DOI:https://doi.org/10.1001/jama.2021.7489.
- Grupper A, Katchman H. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: not alarming, but should be taken gravely. Am J Transplant. 2021;21(8): 2909. Jun 3.
- Rozen-Zvi B, Yahav D, Agur T, et al. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Clin Microbiol Infect. 2021 Aug;27(8):1173 e1–1173 e4. DOI:https://doi.org/10.1016/j.cmi.2021.04.028.
- Rabinowich L, Grupper A, Baruch R, et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. J Hepatol. 2021; 75(2): 435–438. Apr 21.
- Guarino M, Cossiga V, Esposito I, et al. Effectiveness of SARS-Cov-2 vaccination in liver transplanted patients: the debate is open!. J Hepatol. 2021 Aug 3. DOI:https://doi.org/10.1016/j.jhep.2021.07.034.
- Ben Zadok O I, Shaul AA, Ben-Avraham B, et al. Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients - a prospective cohort study. Eur J Heart Fail. 2021;23(9): 1555–1559. May 8.
- Peled Y, Ram E, Lavee J, et al. Third dose of the BNT162b2 vaccine in heart transplant recipients: immunogenicity and clinical experience. J Heart Lung Transplant. 2021 Aug 28.
- Havlin J, Svorcova M, Dvorackova E, et al. Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients. J Heart Lung Transplant. 2021 Aug;40(8):754–758. DOI:https://doi.org/10.1016/j.healun.2021.05.004.
- Shostak Y, Shafran N, Heching M, et al. Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine. Lancet Respir Med. 2021 Jun;9(6):e52–e53. DOI:https://doi.org/10.1016/S2213-2600(21)00184-3.
- Giannella M, Pierrotti LC, Helantera I, et al. SARS-CoV-2 vaccination in solid-organ transplant recipients: what the clinician needs to know. Transpl Int. 2021 Aug 27;34(10):1776–1788. DOI:https://doi.org/10.1111/tri.14029.
- Cucchiari D, Egri N, Bodro M, et al. Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. Am J Transplant. 2021 Aug;21(8):2727–2739. DOI:https://doi.org/10.1111/ajt.16701.
- Hall VG, Ferreira VH, Ierullo M, et al. Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. Am J Transplant. 2021 Aug 4;21(12):3980–3989.
- Chavarot N, Ouedrani A, Marion O, et al. Poor Anti-SARS-CoV-2 humoral and T-cell responses After 2 injections of mRNA Vaccine in kidney transplant recipients treated with belatacept. Transplantation. 2021 Apr 8;105(9):e94–e95.
- Sattler A, Schrezenmeier E, Weber UA, et al. Impaired humoral and cellular immunity after SARS-CoV2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients. J Clin Invest. 2021 Jun 8;131(14). DOI:https://doi.org/10.1172/JCI150175.
- Tsapepas D, Paget K, Mohan S, et al. Clinically significant COVID-19 following SARS-CoV-2 vaccination in kidney transplant recipients. Am J Kidney Dis. 2021 Aug;78(2):314–317. DOI:https://doi.org/10.1053/j.ajkd.2021.05.004.
- Wadei HM, Gonwa TA, Leoni JC, et al. COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccination. Am J Transplant. 2021 Apr 23;21(10):3496–3499.
- Qin CX, Moore LW, Anjan S, et al. Risk of breakthrough SARS-CoV-2 infections in adult transplant recipients. Transplantation. 2021 Nov 1;105(11):e265–e266.
- Kamar N, Abravanel F, Marion O, et al. Three doses of an mRNA Covid-19 Vaccine in solid-organ transplant recipients. N Engl J Med. 2021 Jun 23;385(7):661–662. DOI:https://doi.org/10.1056/NEJMc2108861.
- Del Bello A, Abravanel F, Marion O, et al. Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. Am J Transplant. 2021 Jul 31. DOI:https://doi.org/10.1111/ajt.16775.
- Benotmane I, Gautier G, Perrin P, et al. Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses. JAMA. 2021 Jul 23;326(11):1063.
- Hall VG, Ferreira VH, Ku T, et al. Randomized trial of a third dose of mRNA-1273 Vaccine in transplant recipients. N Engl J Med. 2021 Aug 11;385(13):1244–1246. DOI:https://doi.org/10.1056/NEJMc2111462.
- Jones BE, Brown-Augsburger PL, Corbett KS, et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Transl Med. 2021 May 12;13(593). DOI:https://doi.org/10.1126/scitranslmed.abf1906.
- Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021 Feb 16;325(7):632–644.
- Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021 Jan 21;384(3):238–251.
- Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med. 2021 Jul 14;385(15):1382–1392.
- O’Brien MP, Forleo-Neto E, Musser BJ, et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N Engl J Med. 2021 Aug 4;385(13):1184–1195.
- Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization (EUA) of REGEN-COV (casirivimab and imdevimab). 2020. Available at: https://www.fda.gov/media/145611/download. [Accessed on 1 September 2021].
- Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization (EUA) of sotrovimab. 2021. Available at: https://www.fda.gov/media/149534/download. [Accessed on 1 September 2021].
- Liu C, Ginn HM, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021 Aug 5;184(16):4220–4236 e13.
- Dhand A, Lobo SA, Wolfe K, et al. Casirivimab-imdevimab for Treatment of COVID-19 in solid organ transplant recipients: an early experience. Transplantation. 2021 Jul 1;105(7):e68–e69.
- Dhand A, Lobo SA, Wolfe K, et al. Bamlanivimab for treatment of COVID-19 in solid organ transplant recipients: early single-center experience. Clin Transplant. 2021 Apr;35(4):e14245. DOI:https://doi.org/10.1111/ctr.14245.
- Kutzler HL, Kuzaro HA, Serrano OK, et al. Initial experience of bamlanivimab monotherapy use in solid organ transplant recipients. Transpl Infect Dis. 2021 Jun 3;23(5):e13662.
- Del Bello A, Marion O, Vellas C, et al. Anti-SARS-Cov-2 monoclonal antibodies in solid-organ-transplant patients. Transplantation. 2021 Jun 30;105(10):e146–e147. DOI:https://doi.org/10.1097/TP.0000000000003883.
- Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020 Oct 22;371:m3939. DOI:https://doi.org/10.1136/bmj.m3939.
- Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020 Aug 4;324(5):460–470.
- Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med. 2021 Feb 18;384(7):619–629.
- Libster R, Perez Marc G, Wappner D, et al. Early High-Titer plasma therapy to prevent severe Covid-19 in Older adults. N Engl J Med. 2021 Feb 18;384(7):610–618.
- Fung M, Nambiar A, Pandey S, et al. Treatment of immunocompromised COVID-19 patients with convalescent plasma. Transpl Infect Dis. 2021 Apr;23(2):e13477. DOI:https://doi.org/10.1111/tid.13477.
- Rahman F, Liu STH, Taimur S, et al. Treatment with convalescent plasma in solid organ transplant recipients with COVID-19: experience at large transplant center in New York City. Clin Transplant. 2020 Dec;34(12):e14089. DOI:https://doi.org/10.1111/ctr.14089.
- Naeem S, Gohh R, Bayliss G, et al. Successful recovery from COVID-19 in three kidney transplant recipients who received convalescent plasma therapy. Transpl Infect Dis. 2021 Feb;23(1):e13451. DOI:https://doi.org/10.1111/tid.13451.
- Wahl A, Gralinski LE, Johnson CE, et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature. 2021 Mar;591(7850):451–457. DOI:https://doi.org/10.1038/s41586-021-03312-w.
- Mombelli M, Lang BM, Neofytos D, et al. Burden, epidemiology, and outcomes of microbiologically confirmed respiratory viral infections in solid organ transplant recipients: a nationwide, multi-season prospective cohort study. Am J Transplant. 2021 May;21(5):1789–1800. DOI:https://doi.org/10.1111/ajt.16383.
- Fisher CE, Preiksaitis CM, Lease ED, et al. Symptomatic respiratory virus infection and chronic lung allograft dysfunction. Clin Infect Dis. 2016 Feb 1;62(3):313–319.
- Peghin M, Los-Arcos I, Hirsch HH, et al. Community-acquired respiratory viruses are a risk factor for chronic lung allograft dysfunction. Clin Infect Dis. 2019 Sep 13;69(7):1192–1197.
- Oh DY, Buda S, Biere B, et al. Trends in respiratory virus circulation following COVID-19-targeted nonpharmaceutical interventions in Germany, January - September 2020: analysis of national surveillance data. Lancet Reg Health Eur. 2021 Jul;6 100112. DOI:https://doi.org/10.1016/j.lanepe.2021.100112.
- Petrova VN, Russell CA. Erratum: the evolution of seasonal influenza viruses. Nat Rev Microbiol. 2018 Jan;16(1):60.
- Kumar D, Ferreira VH, Blumberg E, et al. A 5-Year prospective multicenter evaluation of influenza infection in transplant recipients. Clin Infect Dis. 2018 Oct 15;67(9):1322–1329. DOI:https://doi.org/10.1093/cid/ciy294.
- Helantera I, Anttila VJ, Lappalainen M, et al. Outbreak of Influenza A(H1N1) in a kidney transplant unit-protective effect of vaccination. Am J Transplant. 2015 Sep;15(9):2470–2474. DOI:https://doi.org/10.1111/ajt.13285.
- Manuel O, Estabrook M. American society of transplantation infectious diseases community of p. rna respiratory viral infections in solid organ transplant recipients: guidelines from the american society of transplantation infectious diseases community of practice. Clin Transplant. 2019 Sep;33(9):e13511. DOI:https://doi.org/10.1111/ctr.13511.
- Hurst FP, Lee JJ, Jindal RM, et al. Outcomes associated with influenza vaccination in the first year after kidney transplantation. Clin J Am Soc Nephrol. 2011 May;6(5):1192–1197. DOI:https://doi.org/10.2215/CJN.05430610.
- Cordero E, Perez-Romero P, Moreno A, et al. Pandemic influenza A(H1N1) virus infection in solid organ transplant recipients: impact of viral and non-viral co-infection. Clin Microbiol Infect. 2012 Jan;18(1):67–73. DOI:https://doi.org/10.1111/j.1469-0691.2011.03537.x.
- Beck CR, McKenzie BC, Hashim AB, et al. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis. 2012 Oct;206(8):1250–1259. DOI:https://doi.org/10.1093/infdis/jis487.
- DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014 Aug 14;371(7):635–645.
- Mombelli M, Rettby N, Perreau M, et al. Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: a randomized controlled trial. Vaccine. 2018 Oct 1;36(41):6163–6169.
- Natori Y, Shiotsuka M, Slomovic J, et al. A double-blind, randomized trial of high-dose VS standard-dose influenza VACCINE in adult solid-organ transplant recipients. Clin Infect Dis. 2018 May 17;66(11):1698–1704. DOI:https://doi.org/10.1093/cid/cix1082.
- L’Huillier A G, Ferreira VH, Hirzel C, et al. Cell-mediated immune responses after influenza vaccination of solid organ transplant recipients: secondary outcomes analyses of a randomized controlled trial. J Infect Dis. 2020 Jan 1;221(1):53–62.
- Cordero E, Roca-Oporto C, Bulnes-Ramos A, et al. Two doses of inactivated influenza vaccine improve immune response in solid organ transplant recipients: results of transgripe 1-2, a randomized controlled clinical trial. Clin Infect Dis. 2017 Apr 1;64(7):829–838. DOI:https://doi.org/10.1093/cid/ciw855.
- Manuel O, Humar A, Berutto C, et al. Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients. J Heart Lung Transplant. 2011 Jun;30(6):679–684. DOI:https://doi.org/10.1016/j.healun.2011.01.705.
- Manuel O, Pascual M, Hoschler K, et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis. 2011 Jan 15;52(2):248–256.
- Morelon E, Pouteil Noble C, Daoud S, et al. Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination. Vaccine. 2010 Oct 4;28(42):6885–6890.
- Baluch A, Humar A, Eurich D, et al. Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients. Am J Transplant. 2013 Apr;13(4):1026–1033. DOI:https://doi.org/10.1111/ajt.12149.
- Kumar D, Campbell P, Hoschler K, et al. Randomized controlled trial of adjuvanted versus nonadjuvanted influenza vaccine in kidney transplant recipients. Transplantation. 2016 Mar;100(3):662–669. DOI:https://doi.org/10.1097/TP.0000000000000861.
- Mombelli M, Hoschler K, Cavassini M, et al. Seasonal trivalent inactivated influenza vaccine with topical imiquimod in immunocompromised patients: a randomized controlled trial. J Infect. 2021 Jul 21;83(3):354–360.
- Schaffer SA, Husain S, Delgado DH, et al. Impact of adjuvanted H1N1 vaccine on cell-mediated rejection in heart transplant recipients. Am J Transplant. 2011 Dec;11(12):2751–2754. DOI:https://doi.org/10.1111/j.1600-6143.2011.03743.x.
- Katerinis I, Hadaya K, Duquesnoy R, et al. De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant. 2011 Aug;11(8):1727–1733. DOI:https://doi.org/10.1111/j.1600-6143.2011.03604.x.
- Scharpe J, Evenepoel P, Maes B, et al. Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant. 2008 Feb;8(2):332–337. DOI:https://doi.org/10.1111/j.1600-6143.2007.02066.x.
- Dos Santos G, Haguinet F, Cohet C, et al. Risk of solid organ transplant rejection following vaccination with seasonal trivalent inactivated influenza vaccines in England: a self-controlled case-series. Vaccine. 2016 Jun 30;34(31):3598–3606.
- Candon S, Thervet E, Lebon P, et al. Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients. Am J Transplant. 2009 Oct;9(10):2346–2354. DOI:https://doi.org/10.1111/j.1600-6143.2009.02787.x.
- Burbach G, Bienzle U, Stark K, et al. Influenza vaccination in liver transplant recipients. Transplantation. 1999 Mar 15;67(5):753–755.
- Vermeiren P, Aubert V, Sugamele R, et al. Influenza vaccination and humoral alloimmunity in solid organ transplant recipients. Transpl Int. 2014 Sep;27(9):903–908. DOI:https://doi.org/10.1111/tri.12345.
- Dolgin E. mRNA flu shots move into trials. Nat Rev Drug Discov. 2021 Nov;20(11):801–803.
- Ison MG, Szakaly P, Shapira MY, et al. Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipients. Antivir Ther. 2012;17(6):955–964. DOI:https://doi.org/10.3851/IMP2192.
- Ikematsu H, Hayden FG, Kawaguchi K, et al. Baloxavir marboxil for prophylaxis against influenza in household contacts. N Engl J Med. 2020 Jul 23;383(4):309–320.
- Pignotti MS, Carmela Leo M, Pugi A, et al. Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease. Pediatr Pulmonol. 2016 Oct;51(10):1088–1096. DOI:https://doi.org/10.1002/ppul.23561.
- American Academy of Pediatrics Committee on Infectious D. American academy of pediatrics bronchiolitis guidelines C. updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014 Aug;134(2):e620–38.DOI:https://doi.org/10.1542/peds.2014-1666.
- Danziger-Isakov LA, Arslan D, Sweet S, et al. RSV prevention and treatment in pediatric lung transplant patients: a survey of current practices among the international pediatric lung transplant collaborative. Pediatr Transplant. 2012 Sep;16(6):638–644. DOI:https://doi.org/10.1111/j.1399-3046.2012.01744.x.
- Michaels MG, Fonseca-Aten M, Green M, et al. Respiratory syncytial virus prophylaxis: a survey of pediatric solid organ transplant centers. Pediatr Transplant. 2009 Jun;13(4):451–456. DOI:https://doi.org/10.1111/j.1399-3046.2008.01017.x.
- Sester M, Leboeuf C, Schmidt T, et al. The “ABC” of virus-specific T Cell immunity in solid organ transplantation. Am J Transplant. 2016 Jun;16(6):1697–1706. DOI:https://doi.org/10.1111/ajt.13684.
- Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010 Jul;20(4):202–213.
- Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of Cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017 Jan 1;64(1):87–91.
- Gala-Lopez BL, Senior PA, Koh A, et al. Late cytomegalovirus transmission and impact of T-depletion in clinical islet transplantation. Am J Transplant. 2011 Dec;11(12):2708–2714. DOI:https://doi.org/10.1111/j.1600-6143.2011.03724.x.
- Manuel O, Husain S, Kumar D, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis. 2013 Mar;56(6):817–824. DOI:https://doi.org/10.1093/cid/cis993.
- Manuel O, Pang XL, Humar A, et al. An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants. J Infect Dis. 2009 Jun 1;199(11):1621–1628.
- Portela D, Patel R, Larson-Keller JJ, et al. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J Infect Dis. 1995 Apr;171(4):1014–1018. DOI:https://doi.org/10.1093/infdis/171.4.1014.
- Beam E, Lesnick T, Kremers W, et al. Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis. Clin Transplant. 2016 Mar;30(3):270–278. DOI:https://doi.org/10.1111/ctr.12686.
- George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for liver transplantation CMVIG-study group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med. 1997 Aug;103(2):106–113. DOI:https://doi.org/10.1016/S0002-9343(97)80021-6.
- Munoz-Price LS, Slifkin M, Ruthazer R, et al. The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients. Clin Infect Dis. 2004 Nov 1;39(9):1293–1299.
- Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis. 2008 Mar 15;46(6):840–846.
- Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant. 2008 May;8(5):975–983. DOI:https://doi.org/10.1111/j.1600-6143.2007.02133.x.
- Razonable RR, Blumberg EA. It’s not too late: a proposal to standardize the terminology of “late-onset” cytomegalovirus infection and disease in solid organ transplant recipients. Transpl Infect Dis. 2015 Dec;17(6):779–784.
- Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-guidelines of the american society of transplantation infectious diseases community of practice. Clin Transplant. 2019 Sep;33(9):e13512. DOI:https://doi.org/10.1111/ctr.13512.
- Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis. 2005 Mar 1;40(5):704–708.
- Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant. 2006 Sep;6(9):2134–2143. DOI:https://doi.org/10.1111/j.1600-6143.2006.01413.x.
- Witzke O, Nitschke M, Bartels M, et al. Valganciclovir prophylaxis versus preemptive therapy in Cytomegalovirus-positive renal allograft recipients: long-term results after 7 years of a randomized clinical Trial. Transplantation. 2018 May;102(5):876–882. DOI:https://doi.org/10.1097/TP.0000000000002024.
- Reischig T, Kacer M, Hes O, et al. Cytomegalovirus prevention strategies and the risk of BK polyomavirus viremia and nephropathy. Am J Transplant. 2019 Sep;19(9):2457–2467. DOI:https://doi.org/10.1111/ajt.15507.
- Singh N, Winston DJ, Razonable RR, et al. Effect of preemptive therapy vs antiviral Prophylaxis on Cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: a randomized clinical trial. JAMA. 2020 Apr 14;323(14):1378–1387. DOI:https://doi.org/10.1001/jama.2020.3138.
- Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010 May;10(5):1228–1237. DOI:https://doi.org/10.1111/j.1600-6143.2010.03074.x.
- Yong MK, Lewin SR, Manuel O. Immune Monitoring for CMV in Transplantation. Curr Infect Dis Rep. 2018 Mar 14;20(4):4.
- Altaf M, Lineburg K, Crooks P, et al. Pre-transplant cytomegalovirus-specific cellular immunity and risk of viral reactivation following lung transplantation: a prospective cohort study. J Infect Dis. 2020;224(3): 312–317. Dec 4.
- Donadeu L, Revilla-Lopez E, Jarque M, et al. CMV-specific cell-mediated immunity predicts high level of cmv replication after prophylaxis withdrawal in lung transplant recipients. J Infect Dis. 2020;224(3): 526–531. Nov 27.
- Fernandez-Ruiz M, Gimenez E, Vinuesa V, et al. Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment. Clin Microbiol Infect. 2019 Mar;25(3):381 e1–381 e10. DOI:https://doi.org/10.1016/j.cmi.2018.05.010.
- Kumar D, Chin-Hong P, Kayler L, et al. A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients. Am J Transplant. 2019 Sep;19(9):2505–2516. DOI:https://doi.org/10.1111/ajt.15315.
- Jarque M, Crespo E, Melilli E, et al. Cellular immunity to predict the risk of Cytomegalovirus Infection in kidney transplantation: a prospective, Interventional, multicenter clinical trial. Clin Infect Dis. 2020 Dec 3;71(9):2375–2385.
- Kumar D, Mian M, Singer L, et al. An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation. Am J Transplant. 2017 Sep;17(9):2468–2473. DOI:https://doi.org/10.1111/ajt.14347.
- Westall GP, Cristiano Y, Levvey BJ, et al. A randomized study of quantiferon CMV-directed versus fixed-duration valganciclovir prophylaxis to reduce late CMV after lung transplantation. Transplantation. 2019 May;103(5):1005–1013. DOI:https://doi.org/10.1097/TP.0000000000002454.
- Paez-Vega A, Gutierrez-Gutierrez B, Aguera ML, et al. Immunoguided discontinuation of prophylaxis for cytomegalovirus disease in kidney transplant recipients treated with antithymocyte globulin: a randomized clinical trial. Clin Infect Dis. 2021 Jun 22; DOI:https://doi.org/10.1093/cid/ciab574.
- Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017 Dec 21;377(25):2433–2444.
- Anderson A, Raja M, Vazquez N, et al. Clinical “real-world” experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients. Clin Transplant. 2020 Jul;34(7):e13866. DOI:https://doi.org/10.1111/ctr.13866.
- Mori Y, Jinnouchi F, Takenaka K, et al. Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data. Bone Marrow Transplant. 2021 Apr;56(4):853–862. DOI:https://doi.org/10.1038/s41409-020-01082-z.
- Winston DJ, Saliba F, Blumberg E, et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant. 2012 Nov;12(11):3021–3030. DOI:https://doi.org/10.1111/j.1600-6143.2012.04231.x.
- Maertens J, Cordonnier C, Jaksch P, et al. Maribavir for preemptive treatment of cytomegalovirus reactivation. N Engl J Med. 2019 Sep 19;381(12):1136–1147.
- Bonaros N, Mayer B, Schachner T, et al. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin Transplant. 2008 Jan-Feb;22(1):89–97. DOI:https://doi.org/10.1111/j.1399-0012.2007.00750.x.
- Snydman DR, Falagas ME, Avery R, et al. Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study. Transplant Proc. 2001 Jun;33(4):2571–2575. DOI:https://doi.org/10.1016/S0041-1345(01)02101-7.
- Hodson EM, Jones CA, Strippoli GF, et al. Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2007 Apr;18(2):CD005129.
- San-Juan R, Manuel O, Hirsch HH, et al. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH questionnaire-based cross-sectional survey. Clin Microbiol Infect. 2015 Jun;21(6):604 e1–9. DOI:https://doi.org/10.1016/j.cmi.2015.02.002.
- Peters AC, Akinwumi MS, Cervera C, et al. The changing epidemiology of posttransplant lymphoproliferative disorder in adult solid organ transplant recipients over 30 years: a single-center experience. Transplantation. 2018 Sep;102(9):1553–1562. DOI:https://doi.org/10.1097/TP.0000000000002146.
- Allen UD, Preiksaitis JK. Practice ASTIDCo. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: guidelines from the american society of transplantation infectious diseases community of practice. Clin Transplant. 2019 Sep;33(9):e13652.
- Walti LN, Mugglin C, Sidler D, et al. Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): a nationwide cohort study. Am J Transplant. 2021 Jul;21(7):2532–2542.
- AlDabbagh MA, Gitman MR, Kumar D, et al. The role of antiviral prophylaxis for the prevention of epstein-barr virus-associated posttransplant lymphoproliferative disease in solid organ transplant recipients: a systematic review. Am J Transplant. 2017 Mar;17(3):770–781. DOI:https://doi.org/10.1111/ajt.14020.
- Green M, Michaels MG, Katz BZ, et al. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant. 2006 Aug;6(8):1906–1912. DOI:https://doi.org/10.1111/j.1600-6143.2006.01394.x.
- Walti LN, Mugglin C, Sidler D, et al. Association of antiviral prophylaxis and rituximab use with post-transplant lymphoproliferative disorders (PTLD): a nationwide cohort study. Am J Transplant. 2020 Dec 2;21(7):2532–2542.
- Tjy K, Ribeiro RVP, Ferreira VH, et al. Ex-vivo delivery of monoclonal antibody (Rituximab) to treat human donor lungs prior to transplantation. EBioMedicine. 2020 Oct;60:102994.
- QuickStats: Age-Adjusted*. Trends in the Prevalence of Herpes Simplex Virus Type 1 (HSV-1) and Herpes Simplex Virus Type 2 (HSV-2) among adolescents and adults aged 14-49 Years - United States, 1999-2000 Through 2015-2016. MMWR Morb Mortal Wkly Rep. 2018 Feb 16;67(6): 203. DOI:https://doi.org/10.15585/mmwr.mm6706a7.
- Basse G, Mengelle C, Kamar N, et al. Disseminated herpes simplex type-2 (HSV-2) infection after solid-organ transplantation. Infection. 2008 Feb;36(1):62–64. DOI:https://doi.org/10.1007/s15010-007-6366-7.
- Martin-Gandul C, Stampf S, Hequet D, et al. Preventive strategies against cytomegalovirus and incidence of alpha-herpesvirus infections in solid organ transplant recipients: a nationwide cohort study. Am J Transplant. 2017 Jul;17(7):1813–1822. DOI:https://doi.org/10.1111/ajt.14192.
- Abad CL, Razonable RR. alpha herpes virus infections among renal transplant recipients. Semin Nephrol. 2016 Sep;36(5):344–350.
- Lee DH, Zuckerman RA. Practice ASTIDCo. Herpes simplex virus infections in solid organ transplantation: guidelines from the american society of transplantation infectious diseases community of practice. Clin Transplant. 2019 Sep;33(9):e13526. DOI:https://doi.org/10.1111/ctr.13526.
- Seale L, Jones CJ, Kathpalia S, et al. Prevention of herpesvirus infections in renal allograft recipients by low-dose oral Acyclovir. JAMA. 1985 Dec 27;254(24):3435–3438.
- Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004 Jan 1;350(1):11–20.
- Johnston C, Gottlieb SL, Wald A. Status of vaccine research and development of vaccines for herpes simplex virus. Vaccine. 2016 Jun 3;34(26):2948–2952.
- Chaves SS, Zhang J, Civen R, et al. Varicella disease among vaccinated persons: clinical and epidemiological characteristics, 1997-2005. J Infect Dis. 2008 Mar 1;197(Suppl 2):S127–31.
- Geel AL, Landman TS, Kal JA, et al. Varicella zoster virus serostatus before and after kidney transplantation, and vaccination of adult kidney transplant candidates. Transplant Proc. 2006 Dec;38(10):3418–3419. DOI:https://doi.org/10.1016/j.transproceed.2006.10.090.
- Posfay-Barbe KM, Pittet LF, Sottas C, et al. Varicella-zoster immunization in pediatric liver transplant recipients: safe and immunogenic. Am J Transplant. 2012 Nov;12(11):2974–2985. DOI:https://doi.org/10.1111/j.1600-6143.2012.04273.x.
- Arness T, Pedersen R, Dierkhising R, et al. Varicella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis. Transpl Infect Dis. 2008 Jul;10(4):260–268. DOI:https://doi.org/10.1111/j.1399-3062.2007.00289.x.
- Gourishankar S, McDermid JC, Jhangri GS, et al. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant. 2004 Jan;4(1):108–115. DOI:https://doi.org/10.1046/j.1600-6143.2003.00287.x.
- Pergam SA, Limaye AP. Practice ASTIDCo. Varicella zoster virus in solid organ transplantation: guidelines from the american society of transplantation infectious diseases community of practice. Clin Transplant. 2019 Sep;33(9):e13622. DOI:https://doi.org/10.1111/ctr.13622.
- Chaves Tdo S, Lopes MH, de Souza VA, et al. Seroprevalence of antibodies against varicella-zoster virus and response to the varicella vaccine in pediatric renal transplant patients. Pediatr Transplant. 2005 Apr;9(2):192–196. DOI:https://doi.org/10.1111/j.1399-3046.2005.00279.x.
- Danerseau AM, Robinson JL. Efficacy and safety of measles, mumps, rubella and varicella live viral vaccines in transplant recipients receiving immunosuppressive drugs. World J Pediatr. 2008 Nov;4(4):254–258.
- Danziger-Isakov L, Kumar D, Practice A. Vaccination of solid organ transplant candidates and recipients: guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant. 2019 Sep;33(9):e13563.
- Vink P, Ramon Torrell JM, Sanchez Fructuoso A, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial. Clin Infect Dis. 2020 Jan 2;70(2):181–190.
- Hirzel C, L’Huillier AG, Ferreira VH, et al. Safety and immunogenicity of adjuvanted recombinant subunit herpes zoster vaccine in lung transplant recipients. Am J Transplant. 2021 Jun;21(6):2246–2253. DOI:https://doi.org/10.1111/ajt.16534.
- L’Huillier AG, Hirzel C, Ferreira VH, et al. Evaluation of recombinant herpes zoster vaccine for primary immunization of varicella-seronegative transplant recipients. Transplantation. 2021 Jan 19;105(10):2316–2323.
- Centers for Disease Control and Prevention (CDC), U.S. Department of Health & Human Services. What everyone should know about Zostavax. [Accessed on 24 October 2021]. Available at: https://www.cdc.gov/vaccines/vpd/shingles/public/zostavax/index.html
- Centers for Disease Control and Prevention (CDC). FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella. MMWR Morb Mortal Wkly Rep. 2012 Mar 30;61(12):212.
- Gans H, Chemaly RF. Varicella zoster immune globulin (human) (VARIZIG) in immunocompromised patients: a subgroup analysis for safety and outcomes from a large, expanded-access program. BMC Infect Dis. 2021 Jan 11;21(1):46.
- Suga S, Yoshikawa T, Ozaki T, et al. Effect of oral Acyclovir against primary and secondary viraemia in incubation period of varicella. Arch Dis Child. 1993 Dec;696:639–642. discussion 642-3. DOI:https://doi.org/10.1136/adc.69.6.639
- Okuno T, Takahashi K, Balachandra K, et al. Seroepidemiology of human herpesvirus 6 infection in normal children and adults. J Clin Microbiol. 1989 Apr;27(4):651–653. DOI:https://doi.org/10.1128/jcm.27.4.651-653.1989.
- Wyatt LS, Rodriguez WJ, Balachandran N, et al. Human herpesvirus 7: antigenic properties and prevalence in children and adults. J Virol. 1991 Nov;65(11):6260–6265. DOI:https://doi.org/10.1128/jvi.65.11.6260-6265.1991.
- Al Fawaz T, Ng V, Richardson SE, et al. Clinical consequences of human herpesvirus-6 DNAemia in peripheral blood in pediatric liver transplant recipients. Pediatr Transplant. 2014 Feb;18(1):47–51. DOI:https://doi.org/10.1111/petr.12176.
- Fernandez-Ruiz M, Kumar D, Husain S, et al. Utility of a monitoring strategy for human herpesviruses 6 and 7 viremia after liver transplantation: a randomized clinical trial. Transplantation. 2015 Jan;99(1):106–113. DOI:https://doi.org/10.1097/TP.0000000000000306.
- Pellett Madan R, Hand J, Practice A. Human herpesvirus 6, 7, and 8 in solid organ transplantation: guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant. 2019 Sep;33(9):e13518.
- Qu L, Jenkins F, Triulzi DJ. Human herpesvirus 8 genomes and seroprevalence in United States blood donors. Transfusion. 2010 May;50(5):1050–1056.
- Liu Z, Fang Q, Zuo J, et al. The world-wide incidence of Kaposi’s sarcoma in the HIV/AIDS era. HIV Med. 2018 May;19(5):355–364. DOI:https://doi.org/10.1111/hiv.12584.
- Mbulaiteye SM, Pfeiffer RM, Whitby D, et al. Human herpesvirus 8 infection within families in rural Tanzania. J Infect Dis. 2003 Jun 1;187(11):1780–1785.
- Chiereghin A, Barozzi P, Petrisli E, et al. Multicenter prospective study for laboratory diagnosis of hhv8 infection in solid organ donors and transplant recipients and evaluation of the clinical impact after transplantation. Transplantation. 2017 Aug;101(8):1935–1944. DOI:https://doi.org/10.1097/TP.0000000000001740.
- Burra P, Germani G, Adam R, et al. Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J Hepatol. 2013 Feb;58(2):287–296. DOI:https://doi.org/10.1016/j.jhep.2012.10.016.
- Lampertico P, Agarwal K, Berg T, European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370–398. DOI:https://doi.org/10.1016/j.jhep.2017.03.021.
- Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016 Jan;63(1):261–283. DOI:https://doi.org/10.1002/hep.28156.
- World Health Organization (WHO). Hepatitis B Fact Sheet. July 2021. [Accessed on 1 September 2021]. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
- Bonazzi PR, Bacchella T, Freitas AC, et al. Double-dose hepatitis B vaccination in cirrhotic patients on a liver transplant waiting list. Braz J Infect Dis. 2008 Aug;12(4):306–309. DOI:https://doi.org/10.1590/S1413-86702008000400009.
- Te H, Doucette K. Viral hepatitis: guidelines by the American society of transplantation infectious disease community of practice. Clin Transplant. 2019 Sep;33(9):e13514. DOI:https://doi.org/10.1111/ctr.13514.
- Fung J, Wong T, Chok K, et al. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: results up to 8 years. Hepatology. 2017 Oct;66(4):1036–1044. DOI:https://doi.org/10.1002/hep.29191.
- Saab S, Waterman B, Chi AC, et al. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. Liver Transpl. 2010 Mar;16(3):300–307. DOI:https://doi.org/10.1002/lt.21998.
- Dickson RC, Everhart JE, Lake JR, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of diabetes and digestive and kidney diseases liver transplantation database. Gastroenterology. 1997 Nov;113(5):1668–1674. DOI:https://doi.org/10.1053/gast.1997.v113.pm9352871.
- Prieto M, Gomez MD, Berenguer M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl. 2001 Jan;7(1):51–58. DOI:https://doi.org/10.1053/jlts.2001.20786.
- Fabrizio F, Bunnapradist S, Martin P. Transplanting kidneys from donors with prior hepatitis B infection: one response to the organ shortage. J Nephrol. 2002 Nov-Dec;15(6):605–613.
- Belli LS, Perricone G, Adam R, et al. Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J Hepatol. 2018 Oct;69(4):810–817. DOI:https://doi.org/10.1016/j.jhep.2018.06.010.
- Levitsky J, Verna EC, O’Leary JG, et al. Perioperative Ledipasvir-Sofosbuvir for HCV in liver-transplant recipients. N Engl J Med. 2016 Nov 24;375(21):2106–2108. DOI:https://doi.org/10.1056/NEJMc1611829.
- Marroquin CE, Marino G, Kuo PC, et al. Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. Liver Transpl. 2001 Sep;7(9):762–768. DOI:https://doi.org/10.1053/jlts.2001.27088.
- Northup PG, Argo CK, Nguyen DT, et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int. 2010 Oct;23(10):1038–1044. DOI:https://doi.org/10.1111/j.1432-2277.2010.01092.x.
- Bethea ED, Gaj K, Gustafson JL, et al. Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study. Lancet Gastroenterol Hepatol. 2019 Oct;4(10):771–780. DOI:https://doi.org/10.1016/S2468-1253(19)30240-7.
- Durand CM, Barnaba B, Yu S, et al. Four-week direct-acting antiviral prophylaxis for kidney transplantation from hepatitis c-viremic donors to hepatitis c-negative recipients: an open-label nonrandomized study. Ann Intern Med. 2021 Jan;174(1):137–138. DOI:https://doi.org/10.7326/M20-1468.
- Woolley AE, Singh SK, Goldberg HJ, et al. Heart and Lung Transplants from HCV-infected donors to uninfected recipients. N Engl J Med. 2019 Apr 25;380(17):1606–1617.
- Feld JJ, Cypel M, Kumar D, et al. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. Lancet Gastroenterol Hepatol. 2020 Jul;5(7):649–657.
- Hoofnagle JH, Nelson KE, Purcell RH. Hepatitis E. N Engl J Med. 2012 Sep 27;367(13):1237–1244.
- Kamar N, Izopet J, Rostaing L. Hepatitis E virus infection. Curr Opin Gastroenterol. 2013 May;29(3):271–278.
- Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008 Feb 21;358(8):811–817.
- Zhu FC, Zhang J, Zhang XF, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet. 2010 Sep 11;376(9744):895–902.
- Cheungpasitporn W, Thongprayoon C, Ungprasert P, et al. Hepatitis A hospitalizations among kidney transplant recipients in the United States: nationwide inpatient sample 2005–2014. Eur J Gastroenterol Hepatol. 2020 May;32(5):650–655.
- Hanssen DAT, Dackus J, Posthouwer D, et al. Is there a higher risk of a complicated course of hepatitis A in kidney transplant patients?. J Clin Virol. 2020;131:104610.
- Knowles WA. Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). Adv Exp Med Biol. 2006;577:19–45.
- Hirsch HH, Randhawa P, Practice A. BK polyomavirus in solid organ transplantation. Am J Transplant. 2013 Mar;13(Suppl 4):179–188. DOI:https://doi.org/10.1111/ajt.12110.
- Cesaro S, Dalianis T, Hanssen Rinaldo C, et al. ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2018 Jan 1;73(1):12–21.
- Hirsch HH, Randhawa PS. Practice ASTIDCo. BK polyomavirus in solid organ transplantation-Guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant. 2019 Sep;33(9):e13528.
- Knoll GA, Humar A, Fergusson D, et al. Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial. JAMA. 2014 Nov 26;312(20):2106–2114.
- Wojciechowski D, Chanda R, Chandran S, et al. Ciprofloxacin prophylaxis in kidney transplant recipients reduces BK virus infection at 3 months but not at 1 year. Transplantation. 2012 Dec 15;94(11):1117–1123.
- Eid AJ, Ardura MI. Practice ASTIDCo. Human parvovirus B19 in solid organ transplantation: guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant. 2019 Sep;33(9):e13535.
- Suresh S, Upton J, Green M, et al. Live vaccines after pediatric solid organ transplant: proceedings of a consensus meeting, 2018. Pediatr Transplant. 2019 Nov;23(7):e13571. DOI:https://doi.org/10.1111/petr.13571.
- Rand EB, McCarthy CA, Whitington PF. Measles vaccination after orthotopic liver transplantation. J Pediatr. 1993 Jul;123(1):87–89.
- Measles: epidemiology and prevention of vaccine-preventable diseases. the pink book: course textbook - 12th edition. April 2011. Accessed on 24 October 2021. http://www.cdc.gov/vaccines/pubs/pinkbook/meas.html
- American Academy of Pediatrics. Measles. In: Kimberlin DW, Brady MT, Jackson MA, et al., editors. Red book: 2018 report of the committee on infectious diseases. 31st ed. Itasca IL:American Academy of Pediatrics; 2018. p. 537.
- McLean HQ, Fiebelkorn AP, Temte JL, et al. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013 Jun 14;62(RR–04):1–34.